Welcome to our dedicated page for Camp4 Therapeutics SEC filings (Ticker: CAMP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Digging through CalAmp’s filings often means reconciling shifting hardware margins with subscription ARR, untangling LoJack licensing deals, and tracking restructuring charges scattered across hundreds of pages. Stock Titan’s AI-powered analysis turns that challenge into a three-click task.
You’ll find every document the moment it hits EDGAR—whether it’s a CalAmp quarterly earnings report 10-Q filing that breaks down Telematics Products shipments, an 8-K material event explained that covers convertible-note covenants, or a proxy statement executive compensation table detailing turnaround-linked incentives. Our algorithms surface the exact page where CalAmp discloses SaaS churn, backlog, or segment margins, then translate the accounting jargon into plain English so you can act quickly.
Need to monitor CalAmp insider trading Form 4 transactions? Real-time alerts flag when executives buy or sell, complete with context about option expirations. Curious about liquidity? The latest CalAmp annual report 10-K simplified highlights cash burn and debt maturity schedules. Want fast answers? Just search “understanding CalAmp SEC documents with AI” or “CalAmp earnings report filing analysis” and this page appears with concise, investor-ready summaries.
- AI-powered summaries for every filing type—10-K, 10-Q, 8-K, 14A, S-1
- CalAmp Form 4 insider transactions real-time feed
- Comparative charts that map hardware vs. SaaS revenue across quarters
- Keyword jump-links to ARR metrics, LoJack license fees, supply-chain commentary
Stop scrolling through dense PDFs. Stock Titan decodes CalAmp SEC filings explained simply so analysts, portfolio managers, and corporate strategists can focus on decisions, not document hunting.
Camp4 Therapeutics Corp. (CAMP) – Form 4 insider filing
On 06/25/2025, director Richard A. Young received a grant of 9,000 stock options with an exercise price of $1.56 per share. The award was recorded with transaction code “A,” indicating a new acquisition rather than an exercise or sale. All options vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the company’s next annual meeting of stockholders, subject to Mr. Young’s continued board service. The options expire on 06/24/2035.
Following the grant, Mr. Young beneficially owns 9,000 derivative securities linked to CAMP common stock, held directly. No open-market purchases or sales of common shares were reported, and no price was paid for the option grant itself.
Key takeaways for investors
- Routine director compensation: single option grant, modest in size.
- No indication of insider buying or selling of existing shares.
- Grant terms align with standard governance practices (10-year life, one-year vesting).
Camp4 Therapeutics Corp. (CAMP) filed a Form 4 detailing a routine director equity grant. On 06/25/2025, director Michael J. Higgins received a stock option covering 9,000 common shares at an exercise price of $1.56 per share. The option vests in full on the earlier of (i) the first anniversary of the grant date or (ii) the company’s next annual shareholders’ meeting, provided Mr. Higgins remains on the board. The option expires on 06/24/2035. Following the transaction, Mr. Higgins beneficially owns 9,000 derivative securities (options) and disclosed no additional direct or indirect common-stock holdings.
The filing was signed on 06/27/2025 by Josh Mandel-Brehm as Attorney-in-Fact.
Camp4 Therapeutics Corp. (CAMP) – Form 4 insider transaction
Director and 10% owner Andrew J. Schwab reported the grant of 9,000 non-qualified stock options on 25 June 2025. The options carry an exercise price of $1.56 per share and expire on 24 June 2035, providing a 10-year term.
- Vesting: The entire award vests on the earlier of (i) the first anniversary of the grant date or (ii) the next annual meeting of stockholders, subject to Mr. Schwab’s continued board service.
- Ownership status: All 9,000 options are held directly by the reporting person; the filing shows no prior derivative holdings, so the post-grant balance is 9,000 options.
- Transaction code “A” denotes an award rather than an open-market purchase or sale; no cash consideration was paid for the grant (price indicated as $0).
The filing does not disclose any accompanying sales or acquisitions of common shares, nor does it provide earnings or operational data. As such, the Form 4 primarily signals continued equity-based incentive alignment between the director/large shareholder and outside investors.
FAQ
What is the current stock price of Camp4 Therapeutics (CAMP)?
What is the market cap of Camp4 Therapeutics (CAMP)?
What is the primary focus of CAMP4 Therapeutics Corp?
Which therapeutic areas does CAMP4 target?
How does CAMP4’s technology work?
What distinguishes CAMP4's approach from traditional therapies?
What are some key product candidates in CAMP4’s pipeline?
How do regulatory designations impact CAMP4?
Who does CAMP4 collaborate with for its research and development?
What is the scientific rationale behind targeting regRNAs?
